These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37221552)

  • 1. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4
    Soldati S; Bär A; Vladymyrov M; Glavin D; McGrath JL; Gosselet F; Nishihara H; Goelz S; Engelhardt B
    J Neuroinflammation; 2023 May; 20(1):123. PubMed ID: 37221552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium.
    Steiner O; Coisne C; Cecchelli R; Boscacci R; Deutsch U; Engelhardt B; Lyck R
    J Immunol; 2010 Oct; 185(8):4846-55. PubMed ID: 20861356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β2 integrin-mediated crawling on endothelial ICAM-1 and ICAM-2 is a prerequisite for transcellular neutrophil diapedesis across the inflamed blood-brain barrier.
    Gorina R; Lyck R; Vestweber D; Engelhardt B
    J Immunol; 2014 Jan; 192(1):324-37. PubMed ID: 24259506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier.
    Abadier M; Haghayegh Jahromi N; Cardoso Alves L; Boscacci R; Vestweber D; Barnum S; Deutsch U; Engelhardt B; Lyck R
    Eur J Immunol; 2015 Apr; 45(4):1043-58. PubMed ID: 25545837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [No Abstract]   [Full Text] [Related]  

  • 7. [Natalizumab treatment in multiple sclerosis].
    Tanaka M
    Rinsho Shinkeigaku; 2015; 55(8):537-43. PubMed ID: 26156254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
    Auer M; Bauer A; Oftring A; Rudzki D; Hegen H; Bsteh G; Di Pauli F; Berek K; Zinganell A; Berger T; Reindl M; Deisenhammer F
    CNS Drugs; 2022 Oct; 36(10):1121-1131. PubMed ID: 36173556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postarrest stalling rather than crawling favors CD8(+) over CD4(+) T-cell migration across the blood-brain barrier under flow in vitro.
    Rudolph H; Klopstein A; Gruber I; Blatti C; Lyck R; Engelhardt B
    Eur J Immunol; 2016 Sep; 46(9):2187-203. PubMed ID: 27338806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions.
    Man S; Tucky B; Bagheri N; Li X; Kochar R; Ransohoff RM
    J Neuroimmunol; 2009 May; 210(1-2):92-9. PubMed ID: 19345424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin crosstalk allows CD4+ T lymphocytes to continue migrating in the upstream direction after flow.
    Kim SHJ; Hammer DA
    Integr Biol (Camb); 2019 Dec; 11(10):384-393. PubMed ID: 31851360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
    Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA
    Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4
    Nishihara H; Soldati S; Mossu A; Rosito M; Rudolph H; Muller WA; Latorre D; Sallusto F; Sospedra M; Martin R; Ishikawa H; Tenenbaum T; Schroten H; Gosselet F; Engelhardt B
    Fluids Barriers CNS; 2020 Feb; 17(1):3. PubMed ID: 32008573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling.
    Haarmann A; Nowak E; Deiß A; van der Pol S; Monoranu CM; Kooij G; Müller N; van der Valk P; Stoll G; de Vries HE; Berberich-Siebelt F; Buttmann M
    Acta Neuropathol; 2015 May; 129(5):639-52. PubMed ID: 25814153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
    Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
    Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis and Natalizumab.
    Fiore D
    Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.